Literature DB >> 7870999

Antinociceptive effects of the kappa opioid, U50,488: lack of modulation by 5-HT2 antagonists.

L A Dykstra1, K R Powell, Y P Lin.   

Abstract

The kappa opioid, U50,488, was examined alone and in combination with the 5HT2 antagonists, ketanserin, pirenperone and LY 53857. Squirrel monkeys responded under a shock titration procedure in which shock intensity increased every 15 s from 0.01 to 2.0 mA in 30 steps. Five responses terminated the shock for 15 s, after which the shock resumed at the next lower intensity. The level at which the monkeys kept the shock 50% of the time (median shock level/MSL) was determined. U50,488 alone produced dose-dependent increases in median shock level whereas none of the 5-HT2 antagonists altered responding under this procedure. When ketanserin (0.032-5.6 mg/kg) was administered in combination with U50,488, very high doses of ketanserin (3.2-5.6 mg/kg) shifted the U50,488 dose-effect curve to the left. Neither pirenperone (0.032-10.0 micrograms/kg) nor LY53857 (0.01-0.32 mg/kg) altered the U50,488 dose-effect curve in any monkey. Taken together, these data do not support a role for the 5-HT2 system in kappa-induced antinociception in the primate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870999     DOI: 10.1007/bf02247371

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Evaluation of the interactions of serotonergic and adrenergic drugs with mu, delta, and kappa opioid binding sites.

Authors:  P J Monroe; S E Perschke; T Crisp; D J Smith
Journal:  Neurosci Lett       Date:  1991-12-09       Impact factor: 3.046

2.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

Review 3.  The concept of selectivity in 5-HT receptor research.

Authors:  I van Wijngaarden; M T Tulp; W Soudijn
Journal:  Eur J Pharmacol       Date:  1990-06-12       Impact factor: 4.432

4.  Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey.

Authors:  L A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  1990-07       Impact factor: 4.030

5.  Reduction in opioid and non-opioid forms of swim analgesia by 5-HT2 receptor antagonists.

Authors:  J M Kiefel; D Paul; R J Bodnar
Journal:  Brain Res       Date:  1989-10-23       Impact factor: 3.252

6.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

7.  U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists.

Authors:  P F Von Voigtlander; R A Lewis
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1982       Impact factor: 5.067

8.  Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.

Authors:  R M Craft; L A Dykstra
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

9.  Behavioral effects of a novel kappa opioid analgesic, U-50488, in rats and rhesus monkeys.

Authors:  A H Tang; R J Collins
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Apparent antinociceptive properties of piperazine-type serotonin agonists: trifluoromethylphenylpiperazine, chlorophenylpiperazine, and MK-212.

Authors:  J W McKearney
Journal:  Pharmacol Biochem Behav       Date:  1989-03       Impact factor: 3.533

View more
  1 in total

1.  Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze.

Authors:  T H Privette; D M Terrian
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.